- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05689827
Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19
July 11, 2023 updated by: Promomed, LLC
Prospective Multicentre Comparative Randomized Double Blind Placebo Controlled Study of Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After Having the Novel Coronavirus Infection (COVID-19)
This is prospective multicentre comparative randomized double blind placebo controlled study conducted in 6 medical facilities.The objective of the study is to assess the safety and efficacy of the sequential therapy with BRAINMAX®, solution for intravenous infusion and intramuscular injection, and BRAINMAX®, capsules for the treatment of patients with asthenia after having the novel coronavirus infection (COVID-19)
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Upon signing the informed consent form and screening, 160 eligible patients from 18 to 65 years of age with asthenia after having the novel coronavirus infection (COVID-19) were randomized at a 1:1 ratio.
First group received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days; total number of injections for the treatment course is 10 and then orally with the dosage regimen of 2 capsules (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) twice per day for 30 days; total number of capsules for the treatment course is 120.
Second group received Placebo in the same way.
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation
- Federal State Budgetary Research Institution "Research Centre of Neurology"
-
Saint Petersburg, Russian Federation
- OsteoVita LLC
-
Sestroretsk, Russian Federation
- Saint Petersburg State Budgetary Healthcare Institution "Municipal Hospital No. 40 of Kurortny District"
-
Yaroslavl, Russian Federation
- Centre For Evidence-Based Medicine Llc
-
Yaroslavl, Russian Federation
- Medical Centre of Diagnostics and Prevention Plus LLC
-
Yaroslavl, Russian Federation
- State Budgetary Healthcare Institution of Yaroslavl Region "Yaroslavl Region Clinical Hospital for War Veterans - International Elderly People Centre 'Zdorovoe Dolgoletie'
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients able to sign the patient informed consent form for the participation in the clinical study
- Patients of both sexes of 18-65 years of age
- Patient's negative test result for severe acute respiratory syndrome (SARS) -CoV-2 RNA obtained by polymerase chain reaction (PCR) method within 72 hours
- COVID-19 diagnosis documented in the history more than 12 weeks ago*
- Minimum two symptoms of asthenic state: fatigue, atony, dizziness, sleeping disorder, feeling of energy loss and decreased functioning, intellectual function disorder, attention and memory disorder, which appeared during or after COVID-19, retain for more than 12 weeks and cannot be explained by an alternative diagnosis
- Patients capable of following the requirements of the Clinical Study Protocol
- Negative pregnancy test result (for women with the active childbearing potential)
- MFI-20 scale score is more than 30 at the moment of screening.
Exclusion Criteria:
- Allergic reactions to the components of the study product
- Oxygen saturation by pulse oximetry (SpO2) oxygen saturation ≤ 95%
- Depression level score by Hamilton Depression Rating Scale (HDRS) at the screening ≥ 8
- Intracranial pressure rise (for the reason of venous outflow disorder and intracranial tumours)
- Severe hepatic failure
- Severe renal failure
- Chronic liver and hepatic diseases
- Thyroid diseases
- Anaemia
- Malignant tumour of any localization currently or during 5 years before the inclusion into the study except for completely treated carcinoma in situ
- Autoimmune diseases
- Other chronical diseases which, according to the investigator, can cause asthenia
- G lomerular filtration rate (GFR) parameter at screening < 30 mL/min
- Pregnancy or lactation period
- Participation in any other clinical study during the last 3 months
- Tuberculosis, cancers or positive reaction to the HIV infection, hepatitis B & C, syphilis according to the history data
- Severe eyesight and/or hearing disorders, serious articulation disorders and/or other deviations able to prevent the patient from adequate cooperation during the study)
- Mental disorders in the history
- Alcohol, drug abuse or drug dependence in the history
- Patients which, according to the investigator, are obviously or probably incapable of understanding and evaluating this study information within the process of the informed consent form signing, including but not limited to with regard to expected risks and possible discomfort
- Other diseases, symptoms or conditions not listed above, which, according to the investigator, are predicaments for the participation in the clinical study
Exclusion of patients from the study
- Erroneous inclusion (inclusion and exclusion criteria violation).
- Investigator or Sponsor's decision to exclude the patient from the study because of clinically significant deviation from protocol/protocol violation.
- Serious adverse events or adverse events which do not meet the seriousness criteria and which if developed, according to the investigator, can make the patient's further participation in the study harmful for the patient's health or wellbeing.
- Any adverse event (there might be no connection with the study drug intake) requiring the observation, procedures and/or drug treatment not allowed by this study protocol.
- Patient's refusal to continue the participation in the study or his/her lack of discipline.
- Allergic reaction to the study drug intake, which require its discontinuation.
- Patient's wish to prematurely terminate the study for any reason.
- Loss of contact with the patient and his/her absence for the visit.
- Necessity to use a therapy prohibited by this protocol.
- Occurrence of pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ethyl methyl hydroxypyridine succinate + Meldonium
Arm 1 (n=80) received intramuscularly with the dosage regimen of 5 mL of solution (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) once per day for 10 days; total number of injections for the treatment course is 10 and then orally with the dosage regimen of 2 capsules (500 mg of ethyl methyl hydroxypyridine succinate + 500 mg of meldonium) twice per day for 30 days; total number of capsules for the treatment course is 120.
Second group received Placebo in the same way.
|
Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
Other Names:
|
Placebo Comparator: Placebo
Arm 2 (n=80) received Placebo in the same way.
|
Placebo was used in the same way
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Asthenia on a scale Multidimensional Fatigue Inventory (MFI-20) after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Mean decrease of MFI-20 asthenia scale score after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Asthenia on a scale MFI-20 after the completion of the parenteral therapy
Time Frame: From baseline to Visit 3 (day 11)
|
Mean decrease of MFI-20 asthenia scale score after the completion of the parenteral therapy
|
From baseline to Visit 3 (day 11)
|
Asthenia on a scale MFI-20 after the completion of the oral therapy
Time Frame: From Visit 3 (day 11) to Visit 5 (day 41)
|
Mean decrease of MFI-20 asthenia scale score after the completion of the oral therapy
|
From Visit 3 (day 11) to Visit 5 (day 41)
|
Headache on a VAS after the completion of the parenteral therapy
Time Frame: From baseline to Visit 3 (day 11)
|
Score dynamics by VAS for the headache evaluation after the completion of the parenteral therapy
|
From baseline to Visit 3 (day 11)
|
Headache on a VAS after the completion of the oral therapy
Time Frame: From Visit 3 (day 11) to Visit 5 (day 41)
|
Score dynamics by VAS for the headache evaluation after the completion of the oral therapy
|
From Visit 3 (day 11) to Visit 5 (day 41)
|
Fatigue on a FAS-10 scale after the completion of the parenteral therapy
Time Frame: From baseline to Visit 3 (day 11)
|
Score dynamics by FAS-10 scale after the completion of the parenteral therapy
|
From baseline to Visit 3 (day 11)
|
Fatigue on a FAS-10 scale after the completion of the oral therapy
Time Frame: From Visit 3 (day 11) to Visit 5 (day 41)
|
Score dynamics by FAS-10 scale after the completion of the oral therapy
|
From Visit 3 (day 11) to Visit 5 (day 41)
|
Dizziness on a DHI questionnaire after the completion of the parenteral therapy
Time Frame: From baseline to Visit 3 (day 11)
|
Score dynamics by DHI questionnaire after the completion of the parenteral therapy
|
From baseline to Visit 3 (day 11)
|
Dizziness on a DHI questionnaire after the completion of the oral therapy
Time Frame: From Visit 3 (day 11) to Visit 5 (day 41)
|
Score dynamics by DHI questionnaire after the completion of the oral therapy
|
From Visit 3 (day 11) to Visit 5 (day 41)
|
Anxiety on a Beck scale after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Score dynamics by Beck scale after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Anxiety on a Beck scale after the completion of the parenteral therapy
Time Frame: From baseline to Visit 3 (day 11)
|
Score dynamics by Beck scale after the completion of the parenteral therapy
|
From baseline to Visit 3 (day 11)
|
Anxiety on a Beck scale after the completion of the oral therapy
Time Frame: From Visit 3 (day 11) to Visit 5 (day 41)
|
Score dynamics by Beck scale after the completion of the oral therapy
|
From Visit 3 (day 11) to Visit 5 (day 41)
|
Regulatory function on a Kerdo vegetation index after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Changes in values of Kerdo vegetation index after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Regulatory function on a Kerdo vegetation index after the completion of the parenteral therapy
Time Frame: From baseline to Visit 3 (day 11)
|
Changes in values of Kerdo vegetation index after the completion of the parenteral therapy
|
From baseline to Visit 3 (day 11)
|
Headache on a visual analogue scale (VAS) after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Score dynamics by VAS for the headache evaluation after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Sleep Quality on a Pittsburgh sleep quality index (PSQI) after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Score dynamics by PSQI questionnaire after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Fatigue on a Fatigue Assessment Scale (FAS-10) scale after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Score dynamics by FAS-10 scale after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Dizziness on a Dizziness Handicap Inventory (DHI) questionnaire after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Score dynamics by DHI questionnaire after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Cognitive function on a Monreal Gognitive Assessment (MoCA) scale after the completion of the sequential therapy
Time Frame: From baseline to Visit 5 (day 41)
|
Score dynamics by MoCA scale after the completion of the sequential therapy
|
From baseline to Visit 5 (day 41)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 5, 2022
Primary Completion (Actual)
November 10, 2022
Study Completion (Actual)
November 10, 2022
Study Registration Dates
First Submitted
January 18, 2023
First Submitted That Met QC Criteria
January 18, 2023
First Posted (Actual)
January 19, 2023
Study Record Updates
Last Update Posted (Actual)
July 13, 2023
Last Update Submitted That Met QC Criteria
July 11, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Asthenia
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- 3-(2,2,2-trimethylhydrazine)propionate
Other Study ID Numbers
- BRAINMAX_ 2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Ethyl methyl hydroxypyridine succinate + Meldonium
-
Promomed, LLCCompletedCOVID-19 | Asthenia | Cognitive Impairment | Functional MRIRussian Federation
-
Photolitec LLCNational Cancer Institute (NCI); Roswell Park Cancer InstituteRecruitingGlioblastoma Multiforme of Brain | Glioma, SarcomatousUnited States
-
Stanford UniversityActive, not recruitingThyroid Cancer | Anaplastic Thyroid Cancer | Undifferentiated Thyroid CancerUnited States
-
Constellation PharmaceuticalsCompleted
-
Constellation PharmaceuticalsCompletedAdvanced Solid TumorsUnited States
-
Crimson Biopharm Inc.Not yet recruiting
-
Constellation PharmaceuticalsActive, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
TorreyPines TherapeuticsCompletedSjogren's Syndrome | XerostomiaUnited States
-
Assistance Publique Hopitaux De MarseilleCompletedChromaffin-tissue Derived TumorsFrance
-
Thomas Jefferson UniversityRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States